Effect of recombinant granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer |
| |
| Authors: | Toshihiko Kotake Tsuneharu Miki Hideyuki Akaza Yoshinobu Kubota Yasunori Nishio Yosuke Matsumura Kazuo Ota Nobuya Ogawa |
| |
| Institution: | (1) Department of Urology, Center for Adult Diseases, Osaka, 3-3 Nakamichi 1-Chome, Higashinari-Ku, Osaka, Japan;(2) University of Tokyo, Tokyo, Japan;(3) Yokohama City University, Tokohama, Japan;(4) Kyoto University, Kyoto, Japan;(5) Okayama University, Okayama, Japan;(6) Nagoya Memorial Hospital, Nagoya, Japan;(7) Department of Pharmacology, Ehime University School of Medicine, Ehime, Japan |
| |
| Abstract: | Summary The effects of recombinant granulocyte colony-stimulating factor (rG-CSF) on the myelosuppression, especially neutropenia, induced by cancer chemotherapy in patients with urogenital cancer were investigated in a randomized, controlled clinical study. In this study, rG-CSF was given subcutaneously at a dose of 2  g/kg per day for 14 consecutive days. Changes in neutrophil counts were compared between the first (no rG-CSF) and second cycles (rG-CSF treatment period) of chemotherapy. rG-CSF administration was found to be effective in reducing the duration of neutropenia, in elevating the neutrophil nadir, and in reducing recovery time. Based on comparisons between the randomized rG-CSF treatment group (with rG-CSF) and the control group, treatment with rG-CSF resulted in the moderation or prevention of neutropenia and the acceleration of recovery. These results demonstrate that in chemotherapy of patients with urogenital cancer, in which neutropenia is a dose- or schedule-limiting factor, the concomitant use of rG-CSF may enable an increase in the dose (higher single dose or increased dose per unit of time) or shorten the chemotherapy period. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
